设计、合成及具有化学预防潜力的吲哚异喹啉雷帕霉素类化合物的生物评价。
Design, synthesis, and biological evaluation of indenoisoquinoline rexinoids with chemopreventive potential.
机构信息
Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, and the Purdue Center for Cancer Research, Purdue University, West Lafayette, Indiana 47907, USA.
出版信息
J Med Chem. 2013 Mar 28;56(6):2581-605. doi: 10.1021/jm400026k. Epub 2013 Mar 8.
Abstract
Nuclear receptors, such as the retinoid X receptor (RXR), are proteins that regulate a myriad of cellular processes. Molecules that function as RXR agonists are of special interest for the prevention and control of carcinogenesis. The majority of these ligands possess an acidic moiety that is believed to be key for RXR activation. This communication presents the design, synthesis, and biological evaluation of both acidic and nonacidic indenoisoquinolines as new RXR ligands. In addition, a comprehensive structure-activity relationship study is presented that identifies the important features of the indenoisoquinoline rexinoids. The ease of modification of the indenoisoquinoline core and the lack of the necessity of a carboxyl group for activity make them an attractive and unusual family of RXR agonists. This work establishes a structural foundation for the design of new and novel rexinoid cancer chemopreventive agents.
摘要
核受体，如视黄酸 X 受体 (RXR)，是调节众多细胞过程的蛋白质。作为 RXR 激动剂的分子对于预防和控制癌症发生特别有意义。这些配体中的大多数都具有酸性部分，据信这对于 RXR 的激活很关键。本通讯介绍了酸性和非酸性茚并异喹啉作为新型 RXR 配体的设计、合成和生物学评价。此外，还提出了一个全面的构效关系研究，确定了茚并异喹啉雷昔诺素的重要特征。茚并异喹啉核心易于修饰，而且活性不需要羧基，这使它们成为一类有吸引力的、不寻常的 RXR 激动剂。这项工作为设计新型雷昔诺素癌症化学预防剂奠定了结构基础。
相似文献
1
Design, synthesis, and biological evaluation of indenoisoquinoline rexinoids with chemopreventive potential.设计、合成及具有化学预防潜力的吲哚异喹啉雷帕霉素类化合物的生物评价。
J Med Chem. 2013 Mar 28;56(6):2581-605. doi: 10.1021/jm400026k. Epub 2013 Mar 8.
2
Identification, synthesis, and biological evaluation of the metabolites of 3-amino-6-(3'-aminopropyl)-5H-indeno[1,2-c]isoquinoline-5,11-(6H)dione (AM6-36), a promising rexinoid lead compound for the development of cancer chemotherapeutic and chemopreventive agents.3-氨基-6-(3'-氨基丙基)-5H-茚并[1,2-c]异喹啉-5,11-(6H)-二酮（AM6-36）的代谢物的鉴定、合成和生物学评价，这是一种有前途的类视黄醇先导化合物，可用于开发癌症化疗和化学预防药物。
J Med Chem. 2012 Jun 28;55(12):5965-81. doi: 10.1021/jm3006806. Epub 2012 Jun 19.
3
Conformationally Defined Rexinoids and Their Efficacy in the Prevention of Mammary Cancers.构象明确的视黄酸类化合物及其在预防乳腺癌方面的功效。
J Med Chem. 2015 Oct 8;58(19):7763-74. doi: 10.1021/acs.jmedchem.5b00829. Epub 2015 Sep 22.
4
Methods to Assess Activity and Potency of Rexinoids Using Rapid Luciferase-Based Assays: A Case Study with NEt-TMN.使用基于荧光素酶的快速检测方法评估视黄酸类化合物活性和效能的方法：以NEt-TMN为例
Methods Mol Biol. 2019;2019:95-108. doi: 10.1007/978-1-4939-9585-1_7.
5
Design and Synthesis of Indenoisoquinolines Targeting Topoisomerase I and Other Biological Macromolecules for Cancer Chemotherapy.设计和合成吲哚异喹啉类化合物，靶向拓扑异构酶 I 和其他生物大分子用于癌症化疗。
J Med Chem. 2021 Dec 23;64(24):17572-17600. doi: 10.1021/acs.jmedchem.1c01491. Epub 2021 Dec 8.
6
Modeling, Synthesis, and Biological Evaluation of Potential Retinoid-X-Receptor (RXR) Selective Agonists: Analogs of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahyro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and 6-(Ethyl(4-isobutoxy-3-isopropylphenyl)amino)nicotinic Acid (NEt-4IB).潜在维甲酸 X 受体（RXR）选择性激动剂的建模、合成与生物评价：4-[1-(3,5,5,8,8-五甲基-5,6,7,8-四氢-2-萘基)乙炔基]苯甲酸（贝沙罗汀）和 6-(乙基(4-异丁氧基-3-异丙基苯基)氨基)烟酸（NEt-4IB）类似物
Int J Mol Sci. 2021 Nov 16;22(22):12371. doi: 10.3390/ijms222212371.
7
Methods to Generate an Array of Novel Rexinoids by SAR on a Potent Retinoid X Receptor Agonist: A Case Study with NEt-TMN.通过对一种强效类视黄醇X受体激动剂进行构效关系研究来生成一系列新型视黄酸类化合物的方法：以NEt-TMN为例
Methods Mol Biol. 2019;2019:109-121. doi: 10.1007/978-1-4939-9585-1_8.
8
Rexinoids modulate steroid and xenobiotic receptor activity by increasing its protein turnover in a calpain-dependent manner.视黄酸类化合物通过以钙蛋白酶依赖的方式增加其蛋白质周转来调节类固醇和外源性物质受体活性。
J Biol Chem. 2008 Aug 8;283(32):21945-52. doi: 10.1074/jbc.M710358200. Epub 2008 Jun 9.
9
A naturally occurring rexinoid, honokiol, can serve as a regulator of various retinoid x receptor heterodimers.一种天然存在的维甲类化合物，厚朴酚，可以作为各种维甲酸 X 受体异二聚体的调节剂。
Biol Pharm Bull. 2012;35(1):1-9. doi: 10.1248/bpb.35.1.
10
Design, synthesis, and biological evaluation of cytotoxic 11-alkenylindenoisoquinoline topoisomerase I inhibitors and indenoisoquinoline-camptothecin hybrids.细胞毒性11-烯基茚并异喹啉拓扑异构酶I抑制剂及茚并异喹啉-喜树碱杂合物的设计、合成与生物学评价
J Med Chem. 2003 Jul 17;46(15):3275-82. doi: 10.1021/jm0300476.
引用本文的文献
1
Mesoporous Copper-Magnesium Oxide Hybrid Nanocatalyzed Synthesis of 3-Substituted Isocoumarins from 2-Iodobenzoic Acid and Terminal Alkyne under Green Conditions.介孔铜镁氧化物杂化纳米催化在绿色条件下由2-碘苯甲酸和末端炔烃合成3-取代异香豆素
ACS Omega. 2023 Apr 24;8(18):16263-16272. doi: 10.1021/acsomega.3c00710. eCollection 2023 May 9.
2
The Castagnoli-Cushman Reaction.卡斯达格利-库什曼反应。
Molecules. 2023 Mar 15;28(6):2654. doi: 10.3390/molecules28062654.
3
Drug discovery from natural products using affinity selection-mass spectrometry.利用亲和筛选-质谱法从天然产物中发现药物。
Drug Discov Today Technol. 2021 Dec;40:59-63. doi: 10.1016/j.ddtec.2021.10.005. Epub 2021 Oct 21.
4
Discovery of atorvastatin as a tetramer stabilizer of nuclear receptor RXRα through structure-based virtual screening.通过基于结构的虚拟筛选发现阿托伐他汀是核受体 RXRα 的四聚体稳定剂。
Bioorg Chem. 2019 Apr;85:413-419. doi: 10.1016/j.bioorg.2019.01.007. Epub 2019 Jan 10.
5
Molecular dynamics simulations and molecular flooding studies of the retinoid X-receptor ligand binding domain.视黄醇 X 受体配体结合域的分子动力学模拟和分子驱替研究。
J Mol Model. 2017 Mar;23(3):98. doi: 10.1007/s00894-017-3260-9. Epub 2017 Mar 1.
6
Development of a Magnetic Microbead Affinity Selection Screen (MagMASS) Using Mass Spectrometry for Ligands to the Retinoid X Receptor-α.采用质谱法开发用于视黄醇 X 受体-α配体的磁性微珠亲和选择屏幕（MagMASS）
J Am Soc Mass Spectrom. 2017 Mar;28(3):479-485. doi: 10.1007/s13361-016-1564-0. Epub 2016 Dec 13.
7
Design, Synthesis, and Biological Evaluation of Potential Prodrugs Related to the Experimental Anticancer Agent Indotecan (LMP400).与实验性抗癌药物吲哚托康（LMP400）相关的潜在前药的设计、合成及生物学评价
J Med Chem. 2016 May 26;59(10):4890-9. doi: 10.1021/acs.jmedchem.6b00220. Epub 2016 Apr 20.
8
Discovery of potent indenoisoquinoline topoisomerase I poisons lacking the 3-nitro toxicophore.发现不含3-硝基毒性基团的强效茚并异喹啉拓扑异构酶I抑制剂。
J Med Chem. 2015 May 14;58(9):3997-4015. doi: 10.1021/acs.jmedchem.5b00303. Epub 2015 Apr 24.
本文引用的文献
1
Modification at the Lipophilic Domain of RXR Agonists Differentially Influences Activation of RXR Heterodimers.视黄酸X受体（RXR）激动剂亲脂性结构域的修饰对RXR异源二聚体激活的影响存在差异。
ACS Med Chem Lett. 2010 Aug 27;1(9):521-5. doi: 10.1021/ml100184k. eCollection 2010 Dec 9.
2
Targeting the c-Kit Promoter G-quadruplexes with 6-Substituted Indenoisoquinolines.用6-取代茚并异喹啉靶向c-Kit启动子G-四链体
ACS Med Chem Lett. 2010 Jul 1;1(7):306-10. doi: 10.1021/ml100062z. eCollection 2010 Oct 14.
3
Synthesis and biological evaluation of indenoisoquinolines that inhibit both tyrosyl-DNA phosphodiesterase I (Tdp1) and topoisomerase I (Top1).吲哚异喹啉类抑制剂的合成与生物评价，该抑制剂既能抑制酪氨酰-DNA 磷酸二酯酶 I（Tdp1），又能抑制拓扑异构酶 I（Top1）。
J Med Chem. 2013 Jan 10;56(1):182-200. doi: 10.1021/jm3014458. Epub 2012 Dec 21.
4
Identification, synthesis, and biological evaluation of the metabolites of 3-amino-6-(3'-aminopropyl)-5H-indeno[1,2-c]isoquinoline-5,11-(6H)dione (AM6-36), a promising rexinoid lead compound for the development of cancer chemotherapeutic and chemopreventive agents.3-氨基-6-(3'-氨基丙基)-5H-茚并[1,2-c]异喹啉-5,11-(6H)-二酮（AM6-36）的代谢物的鉴定、合成和生物学评价，这是一种有前途的类视黄醇先导化合物，可用于开发癌症化疗和化学预防药物。
J Med Chem. 2012 Jun 28;55(12):5965-81. doi: 10.1021/jm3006806. Epub 2012 Jun 19.
5
Synthesis and biological evaluation of the first dual tyrosyl-DNA phosphodiesterase I (Tdp1)-topoisomerase I (Top1) inhibitors.首个双酪氨酰-DNA 磷酸二酯酶 I（Tdp1）-拓扑异构酶 I（Top1）抑制剂的合成与生物学评价。
J Med Chem. 2012 May 10;55(9):4457-78. doi: 10.1021/jm300335n. Epub 2012 Apr 26.
6
Molecular determinants of magnolol targeting both RXRα and PPARγ.靶向 RXRα 和 PPARγ 的厚朴酚的分子决定因素。
PLoS One. 2011;6(11):e28253. doi: 10.1371/journal.pone.0028253. Epub 2011 Nov 29.
7
Synthesis of substituted isoquinolines via Pd-catalyzed cross-coupling approaches.钯催化交叉偶联方法合成取代异喹啉。
Org Lett. 2011 Dec 2;13(23):6180-3. doi: 10.1021/ol202565j. Epub 2011 Nov 9.
8
The retinoid X receptors and their ligands.维甲酸X受体及其配体。
Biochim Biophys Acta. 2012 Jan;1821(1):21-56. doi: 10.1016/j.bbalip.2011.09.014. Epub 2011 Oct 1.
9
Integrating structure-based and ligand-based approaches for computational drug design.基于结构和基于配体的方法相结合的计算药物设计。
Future Med Chem. 2011 Apr;3(6):735-50. doi: 10.4155/fmc.11.18.
10
Induction of retinoid X receptor activity and consequent upregulation of p21WAF1/CIP1 by indenoisoquinolines in MCF7 cells.诱导视黄酸 X 受体活性和随后的 MCF7 细胞中 p21WAF1/CIP1 的上调由异喹啉吲哚诱导。
Cancer Prev Res (Phila). 2011 Apr;4(4):592-607. doi: 10.1158/1940-6207.CAPR-10-0004.
Zotero 插件